(Q36265996)

13 August 2017

1 reference

title

Torcetrapib/atorvastatin combination therapy (English)

1 reference

13 August 2017

Harold Bays

1

1 reference

PubMed ID

16181026

13 August 2017

James McKenney

series ordinal

2

1 reference

PubMed ID

16181026

13 August 2017

Michael Davidson

series ordinal

3

1 reference

13 August 2017

1 September 2005

1 reference

Expert Review of Cardiovascular Therapy

13 August 2017

1 reference

13 August 2017

3

1 reference

13 August 2017

789-820

1 reference

13 August 2017

5

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

13 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Extended-release niacin/lovastatin: the first combination product for dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Pharmacotherapy for dyslipidaemia – current therapies and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Existing and investigational combination drug therapy for high-density lipoprotein cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Lipoprotein atherogenicity: an overview of current mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Endothelial protection by high-density lipoproteins: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the Theory of Everything

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevalence and Trends in Obesity Among US Adults, 1999-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevalence of the metabolic syndrome in US populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Postprandial lipaemia in familial combined hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Clinical Pharmacokinetics of Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

HDL as a target in the treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Genetics and coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Plasma lipid transfer protein as a determinant of the atherogenicity of monkey plasma lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Clinical trials and lipid guidelines for type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Trans fatty acids and cholesterol metabolism: mechanistic studies in rats and rabbits fed semipurified diets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Unique lipoprotein phenotype and genotype associated with exceptional longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Molecular identification of high and low affinity receptors for nicotinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Torcetrapib and atorvastatin--should marketing drive the research agenda?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.3.5.789

21 January 2018

Identifiers

DOI

10.1586/14779072.3.5.789

1 reference

13 August 2017

1 reference

PubMed ID

16181026